Improving Lives Through
Diagnostic and
Therapeutic Solutions
Exodax is a vertically integrated research and development company
focused on changing diagnosis and treatment for oncology
and SARS-CoV-2 (COVID-19)
COVID-19 TESTING
Exodax has developed the first rapid (10-minute) point-of-care test that measures the concentration of neutralizing antibodies to COVID-19.
CLINICAL THERAPEUTICS
Exodax clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market
CANCER DIAGNOSTICS
Exodax is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer
The Latest On Our Research
Founded in 2014, Exodax is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). Exodax’s NeuCovix is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis.
PHYSIOTHERAPY
Exodax’ Partner Empowered Files EUA With FDA For Use Of Rapid COVID-19 Neutralizing Antibody Test
Mar 24, 2021 | News
Exodax said that its manufacturing partner, Empowered Diagnostics, has filed an Emergency Use Authorization or EUA application with the US Food and Drug Administration for the approval to use ImmunoPass, the company's rapid test that...
Exodax’ Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations
Mar 24, 2021 | Press Release
SAN DIEGO – March 24, 2021 – Exodax (OTCQB: Exodax) (“Exodax® Biotech,” “Exodax” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s manufacturing partner,...
Mar 17, 2021 | News
After a little over a year of expedited research, financial hardship and over 500K deaths in the US, we're finally starting to see the light at the end of the COVID-19 tunnel. But while the widespread rollout of vaccines has been encouraging, there are many additional...